Inflarx N.V. (IFRX) has released an update.
InflaRx N.V., a biopharmaceutical company based in Germany and the Netherlands, reported a comprehensive loss for the first quarter of 2024. The unaudited financial statements showed an operating loss and a negative income for the period, despite generating revenues. The company’s total assets, including cash and cash equivalents, remained substantial.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
